Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIK Cells vs Pemetrexed Maintenance in Advanced Nonsquamous NSCLC
NCT01481259Phase 3Unknown
- Sponsor
- Guangxi Zhuang Autonomous Region People's Hospital
- Start
- Jan 2010
- Primary completion
- Jan 2013
- Modality
- Prophylactic Vaccines, Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of autologous cytokine-induced killer cells in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC) (2 arms), sponsored by Guangxi Zhuang Autonomous Region People's Hospital. Primary endpoint: Progression-free survival at 1 year. Status: unknown.
02
Drugs
autologous cytokine-induced killer cells
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT01481259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01481259.